Corticosteroid Treatment for Recurrent Henoch- Schönlein Purpura with Gastrointestinal Manifestation: A Case Report

Main Article Content

Elizabeth Melina
Felix Nathan Trisnadi


Aims: Henoch-Schönlein Purpura (HSP) is the most common vasculitis during childhood yet sometimes is misdiagnosed. Gastrointestinal symptom in HSP is a frequent finding which causes patient to seek medical care. Recurrent episode of HSP occurs in 2.7–30% cases, most of which has predisposing factors. HSP is usually a self-limiting disease which is managed with supportive treatment. Limited evidence has been reported about the use of corticosteroid for HSP.

Presentation of Case: A 10-year-old girl came with chief complaints of abdominal pain, nausea and vomiting, and palpable purpura in lower extremities a day prior to admission, preceded by upper respiratory tract infection. Patient had history of similar symptoms before, she was diagnosed with recurrent HSP with skin and gastrointestinal manifestations. She was treated with corticosteroid for two weeks and showed clinical improvement during follow-up.

Discussion: Recurrent episode of HSP occurs more frequently in patients with predisposing factors. Although there is no specific recommendation about the use of corticosteroid for HSP, several studies reported benefits of corticosteroid for patients with organ involvement such as gastrointestinal to relieve the pain. We considered giving short-term corticosteroid and observed clinical improvement in our patient.

Conclusion: Identifying predisposing factors for HSP in each patient may help to prevent the recurrence. Despite limited evidence regarding the use of corticosteroid, short-term use of corticosteroid could be considered in HSP with gastrointestinal involvements to relieve the symptoms.

Henoch-Schönlein Purpura, gastrointestinal, corticosteroid, recurrent, pediatrics, case report.

Article Details

How to Cite
Melina, E., & Trisnadi, F. N. (2020). Corticosteroid Treatment for Recurrent Henoch- Schönlein Purpura with Gastrointestinal Manifestation: A Case Report. Asian Journal of Case Reports in Medicine and Health, 4(1), 17-21. Retrieved from
Case Report


Sivaraman V, Fels E, Ardoin S. Henoch-Schönlein purpura. In: Kliegman RM, St Geme III JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, et al., editors. Nelson Textbook of Pediatrics 21st ed. Philadelphia: Elsevier. 2019;317–20.

Reamy BV, Williams PM. Henoch-Schönlein purpura. Am Acad Fam Physician. 2009;80(7):698–704.

Xu Y, Wang JJ, Liu FF, Wu Y, Wu YF, Samadli S, et al. Predisposing factors of childhood Henoch-Schönlein purpura in Anhui province, China. J Investig Med. 2018;1–8.

Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch-Schönlein purpura: An updated review. Autoimmun Rev. 2014;13(4–5):355–8.

George RM, Inamadar AC, Janagond AB. Neutrophil-to-lymphocyte ratio: A biomarker for predicting systemic involvement in IgA vasculitis. Indian J Rheumatol. 2020;15(3).

Kanik A, Baran M, Ince FD, Cebeci O, Bozkurt M, Cavusoglu D, et al. Faecal calprotectin levels in children with Henoch-Schönlein purpura: Is this a new marker for gastrointestinal involvement? Eur J Gastroenterol Hepatol. 2015;27(3):254–8.

Prais D, Amir J, Nussinovitch M. Recurrent Henoch-Schönlein purpura in children. J Clin Rheumatol. 2007;13(1):25–8.

Lei W Te, Tsai PL, Chu SH, Kao YH, Lin CY, Fang LC, et al. Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database. Pediatr Rheumatol. 2018;16(1):8–17.

Weiss PF. Effects of corticosteroids on Henoch-Schönlein purpura: A systematic review. Pediatrics. 2007;120(5):1079–87.

Bluman J, Goldman RD. Henoch-Schönlein purpura in children: Limited benefit of corticosteroids. Can Fam Physician. 2014;60(11):1007–10.

Calvo-Río V, Hernández JL, Ortiz-Sanjuán F, Loricera J, Palmou-Fontana N, González-Vela MC, et al. Relapses in patients with Henoch-Schönlein purpura: Analysis of 417 patients from a single center. Medicine (Baltimore). 2016;95(28).